These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30926561)

  • 1. GLP-1-based therapies to boost autophagy in cardiometabolic patients: From experimental evidence to clinical trials.
    Costantino S; Paneni F
    Vascul Pharmacol; 2019 Apr; 115():64-68. PubMed ID: 30926561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alogliptin improves endothelial function by promoting autophagy in perivascular adipose tissue of obese mice through a GLP-1-dependent mechanism.
    Zhu B; Li Y; Mei W; He M; Ding Y; Meng B; Zhao H; Xiang G
    Vascul Pharmacol; 2019 Apr; 115():55-63. PubMed ID: 30447331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity.
    Yaribeygi H; Sathyapalan T; Sahebkar A
    Life Sci; 2019 Oct; 234():116776. PubMed ID: 31425698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
    Torekov SS
    Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
    [No Abstract]   [Full Text] [Related]  

  • 6. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
    Tzotzas T; Karras SN; Katsiki N
    Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
    Dawwas GK; Smith SM; Park H
    Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming obesity: The advancement of multi-receptor drugs.
    Kusminski CM; Perez-Tilve D; Müller TD; DiMarchi RD; Tschöp MH; Scherer PE
    Cell; 2024 Jul; 187(15):3829-3853. PubMed ID: 39059360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system.
    Aroor AR; Sowers JR; Jia G; DeMarco VG
    Am J Physiol Heart Circ Physiol; 2014 Aug; 307(4):H477-92. PubMed ID: 24929856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretin-based therapies, glucometabolic health and endovascular inflammation.
    Rizzo M; Nikolic D; Banach M; Patti AM; Montalto G; Rizvi AA
    Curr Pharm Des; 2014; 20(31):4953-60. PubMed ID: 24320037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors.
    Darsalia V; Larsson M; Klein T; Patrone C
    Cardiovasc Diabetol; 2018 Feb; 17(1):32. PubMed ID: 29466979
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance?
    Lehmann EW; Torekov SS
    Cardiovasc Res; 2021 Aug; 117(10):e120-e122. PubMed ID: 34448813
    [No Abstract]   [Full Text] [Related]  

  • 15. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
    Yamagishi S; Matsui T
    Curr Pharm Des; 2011 Dec; 17(38):4379-85. PubMed ID: 22204436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Modulation of the incretin effect in the treatment of diabetes].
    Vidal J
    Med Clin (Barc); 2014; 143 Suppl 2():8-11. PubMed ID: 25326837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase-4 inhibitor MK-626 restores insulin secretion through enhancing autophagy in high fat diet-induced mice.
    Liu L; Liu J; Yu X
    Biochem Biophys Res Commun; 2016 Feb; 470(3):516-520. PubMed ID: 26802468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.
    João AL; Reis F; Fernandes R
    Obes Rev; 2016 Jul; 17(7):553-72. PubMed ID: 27125902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelial and Perivascular Adipose Tissue Abnormalities in Obesity-Related Vascular Dysfunction: Novel Targets for Treatment.
    Schinzari F; Tesauro M; Cardillo C
    J Cardiovasc Pharmacol; 2017 Jun; 69(6):360-368. PubMed ID: 28141700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.